FDA appears poised to more quickly increase generic competition with its expanded ANDA prioritization policy, but stakeholders may be disappointed if they expect any immediate gratification from the changes.
Instead of offering priority only to first generics, the agency now will offer it for generics where there are "fewer than three ANDAs approved for the reference listed drug" and there are no blocking patents or exclusivities, according to an updated
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?